Current Status and Strategic Recommendations for Randomized Controlled Trials on Functional Dyspepsia-Irritable Bowel Syndrome Comorbidity：from a Real-World Research Perspective
10.13288/j.11-2166/r.2026.09.005
- VernacularTitle:真实世界研究视角下功能性消化不良-肠易激综合征共病随机对照试验的现状分析及对策建议
- Author:
Ning DAI
1
;
Linlin JIANG
1
;
Huie ZHANG
1
;
Fang LU
1
Author Information
1. Xiyuan Hospital， China Academy of Chinese Medical Sciences，Beijing，100091
- Publication Type:Journal Article
- Keywords:
functional dyspepsia;
irritable bowel syndrome;
comorbidity;
randomized controlled trial
- From:
Journal of Traditional Chinese Medicine
2026;67(9):946-950
- CountryChina
- Language:Chinese
-
Abstract:
By analyzing the current status of randomized controlled trials （RCTs） on functional dyspepsia （FD） and irritable bowel syndrome （IBS） comorbidity， we identified several critical issues which include insufficient repor-ting of FD and IBS subtypes， inadequate risk assessment of drug combination， lack of composite， objective， and long-term outcomes， and weak evidence support for clinical practice guidelines. It is suggested that future clinical research on FD-IBS comorbidity should further strengthen the application of real-world studies. The use of composite outcomes and long-term follow-up is recommended to improve the quality of evidence， while greater attention should be paid to patients' preferences and self-management to enhance the applicability of findings. Based on the existing issues in clinical studies of traditional Chinese medicine （TCM） for FD-IBS comorbidity， we propose to consolidate the foundation of TCM-specific efficacy evaluation to better reflect the advantages of syndrome differentiation and treatment， optimize real-world study designs to better support clinical decision- making， and introduce intelligent objective evaluation technologies to improve the objectivity and accuracy of TCM clinical efficacy assessment.
